The global demand for complex regional pain syndrome (CRPS) market is estimated to be worth around USD 103.7 million in the current year 2023. During the projection period from 2023 to 2033, the market is forecasted to expand at a CAGR of 2.2%. The analysis report by FMI further predicts the market to expand positively during the forecast years rising to USD 129.2 million by 2033.
The increase in the number of individuals suffering from complex regional pain syndrome (CRPS), chronic pain, and failing back syndrome is one of the significant reasons driving market development. Complex regional pain syndrome (CRPS) is a chronic pain disorder that can affect the entire body or only the legs, arms, feet, and hands.
There are two forms of CRPS, each with identical symptoms and treatments. Complex regional pain syndrome (CRPS) Type I arises after an injury without any nerve damage (also known as reflex sympathetic dystrophy). Type II CRPS develops as a result of particular nerve damage or trauma.
The prognosis of complicated regional pain syndrome varies by individual. In most situations, CRPS is minor, and the patient progressively heals over time; but, in other cases, the symptoms are severe, resulting in long-term impairment. Also, CRPS affects both men and women equally, however, women are more likely to be impacted.
The exact etiology of complex regional pain syndrome (CRPS) is unknown. CRPS is caused by an injury or trauma in around 90% of patients. Leg immobility, soft tissue damage, fracture, sprain, or needle stick injuries produced during surgical procedures are all typical causes of injury. Further, in individuals with CRPS, peripheral nerve abnormalities include unmyelinated and weakly myelinated nerve fibers at the axon area, which creates aberrant neurological symptoms.
CRPS tissue has an increased level of inflammatory molecules such as cytokines and it is frequent in people with inflammatory and autoimmune disorders. Currently, the genetic propensity to complex regional pain syndrome is not being studied extensively.
A study on the family incidence of CRPS in Dutch patients discovered that CRPS may occur in a familial form, but the inheritance pattern remained unknown. The number of symptoms and the individual's medical history influence the diagnosis of CRPS. There are just a few diagnostic procedures for CRPS.
According to the incidence statistics, females are three times more impacted than males. Additionally, according to research done in the United Kingdom, one in every 3,800 persons gets CRPS each year. Therapy (Rehabilitation Therapy, Psychotherapy) or pharmaceuticals such as non-steroidal anti-inflammatory drugs, corticosteroids, and others can be used to treat CRPS.
| Attributes or Data Points | Details |
|---|---|
| Global Complex Regional Pain Syndrome (CRPS) Market Valuation in 2022 | USD 101.9 million |
| Estimated Global Market Share in 2023 | USD 103.7 million |
| Forecasted Global Market Size by 2033 | USD 129.2 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 2.2% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 1.4% CAGR |
Explore FMI!
Book a free demo
The global demand for complex regional pain syndrome (CRPS), in terms of value, was nearly USD 95.1 million in the year 2018, according to FMI. During the years from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.4%. By the end of the year 2022, the overall valuation of the market reached about USD 101.9 million.
CRPS is more frequent in women and can occur at any age, according to the National Institute of Neurological Disorders and Stroke (NINDS). Furthermore, 90% of instances were caused by trauma or injury. As a result, several people suffering from chronic pain drive the market growth.
Growth in research and development spending by both private and governmental entities, as well as favorable government legislation, are some of the key drivers projected to drive the market in the next years. Moreover, the Worldwide Research Foundation for RDS/CRPS, for example, developed an international research network to help educate medical professionals and promote research.
A Growing Number of People Suffering from Chronic Pain to Boost Demand
There are currently no medications authorized by the USA FDA for the treatment of complex regional pain syndrome. Physicians, on the other hand, recommended therapy and medications to treat chronic pain.
The USA Food and Drug Administration recently identified Neridronic acid as a breakthrough drug in clinical studies for complex regional pain syndrome. Also, the FDA has granted the medicine Fast-track and orphan drug designations. Intense research and development, an increase in the number of CRPS cases, and the successful completion of clinical studies are expected to accelerate the expansion of the complex regional pain syndrome market.
The growing number of non-profit initiatives, increased research and development funding by private and public organizations, and various government initiatives to raise awareness about the syndrome are expected to drive market growth during the forecast period. For example,
The USA Pain Foundation, a non-profit organization, is committed to supporting persons who suffer from chronic pain disorders. The USA Pain Foundation aims to empower, educate, and connect those suffering from severe chronic diseases.
Rising research and development efforts and FDA approvals of new medications are likely to boost market expansion throughout the forecast period. For example,
The FDA awarded orphan drug classification to Soin Therapeutics, an Ohio-based pharmaceutical firm, in September 2021 for low-dosage Naltrexone (LDN) to treat Complex Regional Pain Syndrome (CRPS).
Tight Regulatory Approval and High Medicine Costs to Hinder Market Growth
In the forthcoming years, tight regulatory approval and high medicine costs may limit the growth of the complex regional pain syndrome market. In addition to this, a dearth of in-depth knowledge of CRPS, a shortage of medical and behavioral pain management professionals, and a dearth of effective treatment choices are the primary challenges impeding the growth of the complex regional pain syndrome market. Furthermore, in poor nations, a dearth of information on the target ailment may limit market growth further.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 58.5% |
| Europe | 14.5% |
Patients' Increased Awareness of Disease Remittance Therapy Creating Opportunities for Complex Regional Pain Syndrome (CRPS) Manufacturers
North America is at the vanguard of regional growth and a significant revenue provider on a worldwide scale. Patients' increased awareness of disease remittance therapy, the expanding frequency of CRPS, and high public and private healthcare spending are all driving the region's rise.
Simple access to high-quality healthcare, good reimbursement regulations, a robust clinical pipeline, and the approval of innovative medications are the important reasons expected to drive revenue growth in North America. Additionally, the increased knowledge of disease remittance therapy among patients, the rising prevalence of CRPS, and high public and private healthcare spending are driving market expansion in these areas.
Simple access to high-quality healthcare, a robust clinical pipeline, and the approval of innovative medications are projected to boost market expansion in North America. Thus, due to the aforementioned reasons, North America possessed a 58.5% market share in 2022, registering a CAGR of 2.1% for the complex regional pain syndrome (CRPS) market in the assessment period between 2023 to 2033.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 48.7% |
| Germany | 4.1% |
| Japan | 3.2% |
Increasing Number of Patients Fueling Significant Adoption
Asia Pacific is expected to be a significantly growing market throughout the projection period. As many people live in cities, several patients in the region are growing. This, combined with rising healthcare spending, is likely to push Asia Pacific’s market. Over the projected period, favorable regulatory rules for medication approval are expected to enhance demand for the regional market.
The key tactics followed by prominent companies in the worldwide complex regional pain syndrome (CRPS) market have been an expansion in emerging countries and a high emphasis on early diagnosis, screening, monitoring, and pharmacological clinical development. Thus, Asia Pacific procured a 35% market share in the year 2022.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 1.4% |
| China | 2.5% |
| India | 2% |
| Australia | 1.8% |
Drug-based Therapy to Remain Highly Sought after
Based on therapy type, drug-based therapy accounted for a great proportion of the complex regional pain syndrome (CRPS) market in 2020. This is mostly due to an increase in the prevalence of several forms of chronic pain, such as lower back pain, severe headache or migraine pain, and face discomfort.
The market for pain reliever medications is predicted to expand throughout the forecast period due to the world's expanding elderly population, sedentary lifestyle, and rising number of surgical operations. Thus, based on therapy type, drugs are anticipated to expand at a 2% CAGR in the complex regional pain syndrome (CRPS) market in the sales indicator period from 2023 to 2033.
| Category | By Therapy |
|---|---|
| Top Segment | Therapy by Drugs |
| Market Share in Percentage | 38.2% |
| Category | By Distribution Channel |
|---|---|
| Top Segment | Hospital Pharmacies |
| Market Share in Percentage | 48.2% |
The Hospital Pharmacy Category is Witnessing Huge Demand in the Complex Regional Pain Syndrome (CRPS) Systems Market
Based on end use, the hospital pharmacy category is predicted to expand at a notable rate in the market during the forecast period. Hospitals are the leading end, consumers of chronic pain treatment products, accounting for a significant market share of the market in 2020.
Pain management strategies are becoming increasingly common in hospitals, particularly for post-surgical pain. As a result of the increasing number of surgical operations worldwide, hospital pharmacy is likely to continue to generate strong demand for complex regional pain syndrome (CRPS).
The most common complex regional pain syndrome (CRPS) techniques are conducted in hospitals, notably for post-surgical pain, where the cost of monitoring and treating side effects creates a strong demand for complex regional pain syndrome (CRPS) medications and technologies. Thus, by distribution channel, the hospital pharmacy category is expected to hold the prominent market share for the complex regional pain syndrome (CRPS) market in the forecast period from 2023 to 2033.
Key Startup Players Operating in the Complex Regional Pain Syndrome (CRPS) Market
Before reaching the brain, the spinal cord stimulation system gathers and suppresses pain impulses. This method consists of a tiny device that, like a pacemaker, sends electrical pulses to the spinal cord. Also, this assists patients in better managing chronic pain and reducing their reliance on opioid drugs.
Nalu Medical is a firm located in the United States of America that is working on an implanted medical device. Also, it is used as an additional treatment for people suffering from persistent pain in the trunk or limbs. The company also provides an External Trial Stimulator (ETS) for use during a Spinal Cord Stimulation (SCS) trial before implanting the permanent device.
Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.
Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market:
| Report Attributes | Details |
|---|---|
| Market Value in 2023 | USD 103.7 million |
| Market Value in 2033 | USD 129.2 million |
| Growth Rate | CAGR of 2.2% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Therapy Type, Route Of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Asia Pacific; The Middle East and Africa |
| Key Countries Profiled | The United States of America, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Japan, South Korea, India, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Mallinckrodt Pharmaceuticals; GlaxoSmithKline plc.; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; AbbVie; ACTAVIS; Zydus Pharmaceuticals Inc.; Sandoz; Janssen Global Services LLC.; Medline Plus |
| Customization | Available Upon Request |
The market may expand at a 2.2% CAGR from 2023 to 2033.
The market in 2022 recorded USD 101.9 million.
China will exhibit a 2.5% CAGR throughout 2033.
AbbVie, ACTAVIS and Sandoz are the key players in this market.
From 2018 to 2022, the market rose at a 1.4% CAGR.
Complex Regional Pain Syndrome (CRPS) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
